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Influenza A continues to cause significant morbidity and mortality.  Vaccine 
production time, viral antigenic variability and low vaccine efficacy contribute to the 
annual pandemics and seasonal epidemics.  A better understanding of human immune 
responses to influenza A could result in more effective vaccines.  Dendritic cells (DCs) 
play an important role in the initiation of immune responses. Populations of B 
lymphocytes secrete protective antibodies but the role of different populations of B cells 
in the protective response is unknown.  In this thesis we developed assays to determine 
subclasses of influenza specific antibodies.  Mononuclear cells were assessed using flow 
cytometry to identify monocytes and marginal zone B lymphocytes. Monocyte-derived 
dendritic cells (MdDCs) were infected with influenza virus A/California/07/2009 
(H1N1pdm) and activation markers were detected by using flow cytometry.  Virus 
infected MdDcs exhibited enhanced expression of CD11c compared to MdDCs exposed 
to inactivated virus.  We hypothesize that the early expression of CD11c activation 
marker is an important event in the early immune response against influenza virus. 
Expression of CD11c may help in the rapid activation of influenza-specific T cells 
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Despite modern medical advances and study, Influenza A viral infection is still a 
serious health problem.  Influenza A has been responsible for several pandemics as well 
as seasonal epidemics during the autumn and winter in some climates, and has been 
known to be detectable all year in tropical climates.  Seasonal influenza epidemics result 
in about three to five million cases of severe illness and 250,000-500,000 deaths 
worldwide according to the World Health Organization17. Deaths due to Influenza A viral 
infection can be caused by secondary infections such as pneumonia, or complications 
from other respiratory or cardiovascular problems19.  Infection with influenza virus also 
has an economic impact due to loss of productivity and missed wages from sick days.  It 
also puts a strain on the healthcare system during peak seasons when a large number of 
patients require care17.  From 1918-1919 the Spanish Flu (H1N1) killed 50 million 
individuals, more than war-related casualties in World War I.  The 1957 Asian Flu 
(H2N2) and 1968 Hong Kong Flu (H3N2) combined killed 2 million individuals.  The 
H5N1 outbreak in 1997 had a 50% mortality rate
16.  More recently, the 2009 pandemic 
H1N1 pandemic virus has killed an estimated 283,000 individuals (respiratory and 
cardiovascular deaths) during the first 12 months, with 80% of the deaths in individuals 
less than 65 years of age18. 
Influenza A is responsible for major pandemics and Influenza B only causes cold-
like symptoms16.  The nomenclature used to describe Influenza A is designated as 
follows: “type of virus/city of isolation/laboratory identification/year (Antigen (HA and 
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NA identifiers).”  If the strain described produces a pandemic, the label “pdm” is used.  
For this research, the strains used were: A/Brisbane/10/2007 (H3N2) and the 
A/California/07/2009 (H1N1pdm) obtained from the Influenza Reagent Resource of the 
Center for Disease Control (CDC).   
According to the CDC, the most effective mean to prevent influenza infection is 
through vaccination26.  There are several different types of influenza vaccines available.  
A standard intramuscular trivalent vaccine is produced in eggs and provides protection 
against three selected flu viruses for that season (usually Influenza B and two Influenza A 
strains). There is also an intradermal trivalent vaccine produced in cultured cells, 
essentially making the vaccine egg free for individuals with egg allergies.  In addition, a 
high-dose trivalent vaccine is available for individuals older than 65.  A quadrivalent flu 
vaccine protects against two selected Influenza A viruses and two selected Influenza B 
viruses.  It is available as a standard vaccine and as a nasal spray.  For the 2013 to 2014 
flu season about 135-139 million vaccine doses were produced in the US27.  It is this 
trivalent vaccine that is the most commonly administered in the northern hemisphere.  It 
contains A/California/7/2009 (H1N1), A H3N2 virus like A/Victoria/361/2011, and 
B/Massachusetts/2/2012 like virus29.   
In spite of available vaccines, predicting which influenza strains will prevail 
during future seasons is a challenge and therefore, effective vaccine production for future 
infections remains non-practical.  Throughout the year, samples from individuals 
suspected of having influenza are sent to the National Influenza Centers from around the 
world.  Here specific strains are identified and details sent to the Collaborating Centers 
for Influenza Reference and Research.  Twice a year this data is evaluated by the WHO 
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Collaborating Center.  Then the strains of influenza likely to cause disease in the next 
season are reviewed and suggestions made for next season’s flu vaccine. Northern 
hemisphere vaccines are reviewed in February and the southern hemisphere in 
September.   Subsequent to this evaluation, manufacturing companies have about 6 
months to produce their vaccine supply.  The majority of the vaccine supply is produced 
in chicken eggs28. There are two types of vaccines, attenuated and inactivated.  
Attenuated vaccines contain a weakened form of the live virus that does not cause disease 
in normal individuals.  Inactivated vaccines contain the virus killed by heat or radiation.  
These vaccines do not require special storage conditions44. 
Serum anti-influenza antibodies after vaccination with inactivated vaccines 
increase in humans two weeks after vaccination.  This protects individuals during the 
influenza season when the highest risk for exposure is present31.  Clinical studies on 
“Afluria” (trivalent inactivated vaccine currently available) showed a vaccine efficacy 
was 60% (lower limit of the 95% confidence interval: 42%) for the 2013-2014 formula32. 
According to the CDC, for the 2013-14 flu season, only 40% of the eligible 
population in the United States had been vaccinated with the seasonal flu vaccine by the 
early part of the season (November 2013)36.  Data is not available for late season vaccine 
coverage but the CDC has estimated it to be around 45% for that time period37.  As of the 
end of February 2014, 95% and 3.8% of the reported influenza associated hospitalizations 
have occurred from Influenza A and Influenza B strains, respectively.  The majority of 
the hospitalizations (61.2%) have occurred in adults age 18-64 years.  Adults over 65 
years of age have only accounted for 24.8% of influenza associated hospitalizations this 
season.  It is important to note that of the Influenza A related hospitalizations, 98.6% 
4 
 
were caused by the pandemic H1N1 strain
36.  This strain has been present in the vaccine 
for several seasons in a row.  Therefor H1N1 is still the major cause of influenza cases 
occurring in non-elderly populations.  
The influenza virion is enveloped with a segmented single-stranded negative 
RNA genome.  It also contains a matrix between the envelope and the nucleocapsid.  The 
influenza virus has 8 genes. Genes 1-3 are related to RNA polymerization and duplication 
of the viral genome.  Gene 4 regulates expression of the HA antigen, or hemagglutinin, 
the viral attachment protein target of neutralizing antibodies.  Gene 5 regulates 
expression of NP or nucleoprotein.  The NP is associated with the viral RNA and a target 
for cellular immunity.  Gene 6 regulates expression of NA, or neuraminidase, which 
cleaves sialic acid and promotes viral release from the host cell.  Neuraminidase is a 
target for neuraminidase inhibitor drugs and neutralizing antibodies of the host.  Gene 7 
codes for the matrix protein 1 (M1), or the viral structure protein, and M2, a membrane 
protein.  Gene 8 codes for Nonstructural Protein 1 and 2 (NS1 or NS2)13.   
The HA and NA combine to form different variants of the influenza virus.  
Human influenza virus strains bind sialic acid attached to galactose in an alpha 2, 6 
configuration present in the glycocalyx of cells, in particular the upper respiratory tract.  
Avian influenza viruses bind the alpha 2, 3 configuration.  Pigs have either configuration 
which causes them to be easily infected with human and avian virus strains, increasing 
the potential for creating novel influenza viruses that could cause human pandemics16.  If 
a pig becomes infected simultaneously with both avian and human Influenza A, a 
recombinant form of the virus may emerge.  This may have an environmental advantage 
and infect new hosts easily because of a lack of herd immunity against the new strain.   
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Influenza is transmitted through droplets and aerosols suspended in the air and 
moved by currents. The human infectious dose is between one and five viral particles.  In 
the infective mode, the virus enters the cell by receptor-mediated endocytosis.  The low 
pH in the endosome allows the membrane of the virus to fuse with the endosome while 
the RNA is delivered to the nucleus.  There, the negative stranded viral RNA transcribes 
to positive RNA to create mRNA.  In the ER transcribed viral mRNAs are translated.  
HA and NA antigens are transported with the help of M2 proteins from the Golgi 
network to the plasma membrane on the apical side of the respiratory epithelium.  The 
negative RNA and other structural proteins move to the cell membrane where the virus is 
assembled.  The virus then buds through the plasma membrane whilst still attached to the 
sialic acid receptors via HA interaction.  NA then cleaves the attaching sialic acid 
releasing the virions into the lumen of the respiratory tract16, 21.   
The incubation period for influenza is about two days.  Thereafter, the onset of the 
disease is fast.  Symptoms include high fever, headaches, chills, cough, congestion, sore 
throat, muscle pain, and loss of appetite.  It takes about a week for the respiratory 
symptoms to subside, but cough and general weakness lasts for up to two weeks.  
Influenza infection leads to cell death and desquamation of the epithelium.  This 
increases the possibility of secondary infections to occur as well as other complications if 
the human immune system cannot stop viral replication.  Secondary bacterial infections 
can occur after influenza infection, causing increased complications and health risks 
including hospitalization and death16.   
An effective vaccine induces host protection by prompting a virus-specific 
neutralizing antibody response. There are a number of antibody isotypes present in 
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human serum. Immunoglobulin G (IgG) makes up about 75% of serum immunoglobulin 
and is involved in the secondary immune response, i.e., the one elicited after an initial 
and subsequent exposure to the same antigens.  IgGs come in several subclasses; IgG1, 2, 
3, and 4.  IgG1 binds Fc- receptors on phagocytic cells and to platelets with high affinity. 
IgG1 has a freely flexing hinge, 15 amino acids in length, and a kappa to lambda light 
chain ratio of 2.4.  It makes up 60.3-71.5% of IgG in healthy adult serum (5-12 g/L).  In 
contrast, IgG2 is the only IgG that cannot cross the placental barrier, and is lacking in 
children less than 2 years of age.  It has a very short hinge that cannot pivot, and is 12 
amino acids long.  The light chain is joined about one fourth the distance from the 
gamma, and has a kappa to lambda ratio of 1.1.  IgG2 constitutes 19.4-31% of IgG in 
healthy human serum (2-6 g/L).  The circulating concentration of IgG2 is highly 
correlated to polysaccharide vaccine responses. IgG3 makes up 5-8.4% of IgG in healthy 
adult serum (0.5-1 g/L) and has a very long hinge region that is 62 amino acids long.  
Complement component C1q binds IgG3 more readily than others.  IgG4 makes up 0.7-
4.2% of IgG in healthy adults serum (0.2-1 g/L), and has a kappa to lambda binding ratio 
of 8.  IgG4 has the shortest hinge (12 amino acids), and is thought to not be able to bind 
compliment through the classical pathway14.   
Contrary to IgGs, Immunoglobulin M (IgM) is less abundant in (1.5 mg/ml of 
serum) and has a pentameric structure.  IgM is the first antibody response detected during 
an infection23.  Its structure allows it to bind antigen with high avidity and agglutinate.  
IgM removes antigen and apoptotic cells from the site of inflammation.  Over the course 
of an infection, the antibody response changes from IgM to IgG40. 
Dendritic cells (DCs) are also found on mucosal surfaces in the respiratory tract. 
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Because of the pivotal role of DCs in initiating and enhancing specific immune 
responses, DCs are used to study the immune system in vitro in many different infection 
models.  The immune response to pathogens not only includes the humoral response i.e., 
antibodies, it also starts with antigen presentation, a task mainly executed by DCs.  These 
cells capture, process, and present antigens.  A process that may be further stimulated by 
foreign particles or by inflammation.  Processed antigens are then bound to the Major 
Histocompatibility Complex (MHC) class I, which then are presented by DCs to CD8 
cytotoxic T cells to activate them to kill the infected targets.  Influenza proteins acquired 
by the exogenous pathway are associated with MHC II proteins and presented by DCs to 
CD4 follicular T helper cells.  Once T helper cells are activated they modulate the 
response of other immune cells such as B cells to induce antibody production i.e., the 
humoral response.  DC-activated T helper cells are involved in class switching of 
activated B cells i.e., the change in the humoral response from isotype IgM to isotype 
IgG41.   
All populations of B cells express CD19, a pan-B cell marker.  A cell population 
of importance in the early antibody response is a B cell subpopulation called the Marginal 
Zone B cells (MZBCs).  The existence of the counterpart of the MZBCs in humans was 
initially controversial but it is now becoming widely accepted3.  MZBCs originate from 
the marginal zone of the spleen, where they come into contact with pathogens in the 
blood4.  The main markers that allow for characterization of the MZBC population in 
humans are CD27 and surface immunoglobulin (Ig) IgD and IgM. MZBCs differ from 
naïve B cells in their expression of CD27, and differ from memory B cells in their 
expression of IgD and IgM.  MZBCs are classified as an innate-like population of B cells 
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and seem to be responsible for the early antibody response in acute infection. Our lab has 
previously demonstrated that this population produces the first wave of neutralizing 
antibodies in mice infected with foot-and-mouth disease virus (FMDV), a virus that 
produces acute infections, is characterized by the secretion of IgM and IgG31, 2. 
 As previously mentioned, T helper cells are necessary to activate B cells in 
humans and to induce the class switch of immunoglobulins from IgM to IgG as part of 
the normal immune response. However, experiments done by researchers working with 
several viruses producing acute infection including influenza virus5, 6 as well as the work 
in our lab with FMDV demonstrated that the early immune response against these viruses 
is T cell independent though there is switch to the IgG isotype1,2. These experiments 
showed that the immune response induced by infection is different than the one elicited 
by vaccination with inactivated virus, which are typically T cell dependent. Nevertheless, 
vaccination with inactivated virus induces a weak and short-lasting antibody response 
compared to the strong and long-lasting antibody response induced by the infection. A 
better understanding of these different pathways involved in early and late immune 
responses to infection as well as the humoral responses to infection or inactivated 
vaccines may help design and produce more efficient next-generation vaccines to prevent 









Purpose and Aim 
The purpose of this study was to analyze the role of DCs in the early immune 
response against infectious and inactivated influenza virus A/California/07/2009 
(H1N1pdm) and to determine the isotype and IgG subclass responses to influenza vaccine 
in normal healthy donors.   
The first specific aim of this study was to determine the expression of activation 
markers in DCs infected with H1N1, inactivated H1N1, and mock infected.  This was 
completed by optimizing the following methods: propagation of influenza virus, titration 
of virus using hemagglutination assay, Tissue Culture Infectious Dose 50% assay 
(TCID50%), enrichment of monocytes from PBMCs, differentiation of monocytes to 
DCs, infection of DCs, and detection of different activation markers using flow 
cytometry.  
We tested the hypothesis that DCs respond differentially to infectious or 
inactivated virus impacting the antibody response against virus presented by DCs.  
The second specific aim of this research was to study the formation of different 
immunoglobulin isotypes both before and after vaccination of normal healthy subjects.  
For this purpose, a series of sandwich Enzyme Linked Immunosorbent Assays (ELISAs) 
were developed to determine the immune of total Immunoglobulin M, total IgG, and 
subclasses IgG1, IgG2, IgG3, and IgG4 and to develop H1 and H3 Influenza A specific 




Figure 1: Experimental design for this thesis project.  Numbers indicate which specific 








This study used healthy volunteers with no known clinical influenza infections in 
the past 2 years, under an approved IRB# 4884 (see appendix A for consent form).   
Table 1: Subjects 
Donor Age at 
collection 
Gender 
A 23 years Female 
B 28 years Male 
C 22 years Male 
D 24 years Male 
E 23 years Male 
F 24 years Female 
H 22 years Male 
I 60 years Female 
L 49 years Female 








Chapter 1: Virus Work 
Section 1: Propagation of Influenza Virus in Embryonated Chicken Eggs  
1.1 Methods 
Stock virus obtained from Influenza Reagent Resource (IRR) was propagated to 
produce enough virus stock for future experiments.  Fertilized chicken eggs were 
obtained for this use (see Figure 2 for an overview).  Each egg was candled to confirm 
the presence of a yolk, insure shell integrity, and location of the air sac.  A piece of tape 
was placed on one side, and the eggs were laid tape up in an incubator at 37 degrees 
Celsius with a beaker of water at the bottom.  Each morning at the same time eggs were 
candled to check for embryo growth, and turned 180 degrees.  On day 10 or 11, eggs 
were candled again, and those with embryos were marked for the air sac location and 
placed into groups.  Dilutions of stock virus were made in sterile 1% Pen-Strep HBSS.  In 
a sterile hood, each embryonated egg was swabbed with 70% ethanol, allowed to dry, and 
a tiny hole was punched at the top where the air sac was.  This hole was then swabbed 
with 70% ethanol again and allowed to dry.  Once dried, 0.2 mls of viral dilution was 
injected at a 45 degree angle into the allantoic sac (0.1 to 0.01 HAU, see Figure 3).  The 
hole was then swabbed with 70% ethanol, allowed to dry, and the hole taped and labeled.  
The eggs were placed back into the incubator for 48 hours and turned daily at the same 
time.  After 48 hours eggs were placed at 4°C overnight to clot the blood.  Allantoic fluid 
was collected in a sterile environment using a syringe.  If a large volume was obtained, 
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the tubes were spun at 500xG at 4 degrees Celsius for 15 minutes to pellet the protein.  
The supernatant was collected, aliquoted and stored at -80 degrees Celsius. 
 
 
Figure 2: Propagation of Influenza A in embryonated chicken eggs.  
Overview of methods. 
Figure 3: Injection of virus into chicken egg.  
Needle was inserted at an angle to ensure that 
virus was injected into the allantoic fluid and 




Allantoic fluid was collected according to the protocol described, and frozen at -
80 degrees Celsius.  Virus presence was determined by using a Hemagglutination Assay 
(HA), as described in section 3.  Because virus propagation in embryonated chicken eggs 
did not produce consistent results, propagation of virus was assayed in MDCK cells. 
Section 2: Propagation of Influenza Virus in Madin Darby Canine Kidney-ATL 
cells (MDCK) 
2.1 Methods 
 MDCK cells were grown in Dulbecco’s Modified Essential Medium (DMEM) 
with 5-10% fetal calf serum (FCS).  FCS was heat inactivated by incubation at 56 degrees 
Celsius for 40 minutes.  The original cell line was obtained from the Influenza Reagent 
Resource.  This was thawed and diluted into a final volume of 10 mls of DMEM-
10%FCS and washed twice at 250xG for 5 minutes at room temperature.  The cell pellet 
was resuspended in 5 mls of DMEM-10%FCS and placed in a 25cm2 tissue culture flask 
and allowed to grow to confluence.  Once confluent, cells were detached by using 0.25% 
Trypsin solution (Thermo Scientific CAT# SH30042.02).  A stock of cells from the 
second passage was frozen back for future use.  Briefly, cells were pelleted by spinning at 
250xG for 5 minutes at room temperature.  The supernatant was removed and the cell 
pellet was resuspended in 10% Dimethyl Sulfoxide (DMSO) DMEM-20% solution at a 
concentration of 1 million cells per ml and dispensed into 1 ml aliquots in cryo-vials.  
These tubes were stored at -80 degrees Celsius for 2 days, then transferred to liquid 
nitrogen for long term storage.  Once cells reached a passage of 30, a new vial of fresh 
cells was thawed and used.   
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For infection, MDCK-ATL cells were grown to confluence in a 75cm2 tissue 
culture flask, see Figure 4 for an image on the growth of the cell line.  Once at confluence 
the growth media was removed and the monolayer washed two times with 5 mls sterile 
Hank’s Balanced Salt Solution (HBSS) with 1% Pen Strep at room temperature.  The 
virus samples were diluted in Influenza Virus Growth Media (0.1 HAU-0.0001 HAU).  
Each flask was inoculated with 1 ml of virus dilution and rotated so solution covered the 
monolayer.  Flasks were incubated at 37 degrees Celsius with 5% CO2 for one hour and 
rotated every 15 minutes to ensure the monolayer did not dry out.  After inoculation, 14 
mls of DMEM-5%FCS was added to each flask, and returned to the incubator.  
Cytopathic effect (CPE) was observed daily, and when 75% of the cell monolayer had 
rounded up and detached the supernatant was removed.  Supernatant was spun at 250xG 
for 20 minutes to pellet cellular debris and the clarified supernatant was aliquoted and 
frozen at -80 degrees Celsius. 
 
 





Cytopathic effect (CPE) was observed in the flasks inoculated with H1N1 virus 
usually on day 3 of infection compared to the controls.  CPE in this project is seen when 
the cell monolayer begins to round up and detach.  When 75% or more of the cells 
exhibited CPE, the supernatant was collected and purified according to the protocol.  
Virus was quantified using a Tissue Culture Infectious Dose 50% Assay (TCID50%, and 
a Hemagglutination Assay (HA), as described in section 3.  H1N1 was easily propagated 
in tissue culture.  As described, dilutions of the stock virus were infected to the MDCK 
cell monolayer, and 0.01 HAU of H1N1 was determined to be optimal for viral 
propagation after the initial experiment (see Figure 5) and used in all remaining 
propagations.  Figure 6 shows an example of an optimized propagation of H1N1 done in 





Figure 5: Propagation of H1N1 in MDCK-ATL cells with different dilutions of stock 




Propagation of H3N2 was not as efficient in tissue culture when compared to 
H1N1.  This can be seen by the low amount of CPE in H3N2 infected samples in Figure 7.  
Because H3N2 did not propagate well in tissue culture, it was not used for this thesis 
work.     
 
Figure 7: H3N2 did not propagate well in MDCK cells, as seen by the low amount of CPE 
compared to the control through day 4 
Figure 6: Propagation of H1N1 in MDCK-ATL cells.  Typical CPE observed on day 3.  




In conclusion, H1N1 was propagated in MDCK cells, as seen in Figure 5 and 6.  
H3N2 did not show any CPE when propagated in MDCK cells, as seen in Figure 7.   
In order for a productive infection to be produced, the virus must be released from 
the host cell.  HA must be cleaved and the NA must be released, as described in the 
introduction.  MDCK cells lack the protease needed to cleave HA into the two subunits.  
By adding tosyl-phenylalanyl-chloromethyl ketone (TPCK)-Treated Trypsin, the HA can 
now be cleaved, and a productive infection can occur22.  
Section 3: Titration of Virus using Hemagglutination 
3.1 Methods 
A 1% Turkey red blood cell (TRBCs) or chicken red blood cell solutions were 
prepared from a stock 5% solution in cold Alsever’s solution.  A white 96 well round 
bottom plate was used to make viral dilutions. Fifty microliters of 1x Phosphate Buffered 
Saline (PBS) were dispensed in each well.  One row served as controls, receiving no 
virus but vehicle.  In the first column 50 µl of virus sample being tested was added to 
make the first 1:2 dilution.  A multichannel pipette was used to mix the well 5 times.  
Two fold dilutions were performed, mixing between each step.  Fifty microliters of 1% 
TRBCs were then added to each well.  The plate was covered, and placed at 4 degrees 
Celsius 45 minutes or until agglutination of the blood was observed.   
Hemagglutination assay determines the number of particles present per unit 
volume of the virus, but it does not determine if the particles are infectious.  The viral 
hemagglutinin protein attaches to the RBCs and binds or agglutinates them, preventing 
them from settling out of suspension and forming red cell agglutination or cell button.  
This button can be seen in the negative control in Figure 8, where the RBCs have pooled 
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to the bottom of the well making a red circle.  RBCs not bound by virus sink to the 
bottom.  This is shown in Figure 8.  The dilution demonstrating agglutination is one 
hemagglutination unit or HAU. 
 
3.2 Results 
Stock virus from the IRR was shipped with no reported concentration of total 
virus particles.  HA assay was used for the stock virus strains to determine the starting 
amount of virus that was used to propagate in MDCK cells, as described previously in 
this chapter.  For influenza virus, 1 HAU=106 virus particles42.  The HAU titer was 
determined for both H1N1 and H3N2 stock vial strains from the IRR.  For H1N1 the 1:32 
dilution of virus was 1 HAU.  For H3N2 the 1:128 dilution of virus was 1 HAU.   
One example of typical results can be seen in Figure 9.  The last dilution that the 
TRBCs are still being held into suspension (no button) is seen at a 1:64 dilution of the 
virus for this example.  A 1:64 dilution of the propagated virus was 1 HAU, or 106 total 
viral particles. 
Figure 8: HA assay. Hemagglutination occurs when virions and red blood cells bind together, and 
produce a net.  As a consequence of the net, the virions and red blood cells remain in suspension.  
A negative result is detected when there is not enough virus present to agglutinate the RBCs, 





The H3N2 virus did not show CPE during the propagation in MDCK cells, as 
previously stated.  When a HA assay was completed on the supernatant from this 
propagation, all results were negative, as seen in Figure 10.  This confirmed the results 





Figure 9: HA assay of H1N1 propagated in MDCK cells.  The endpoint was 
1:64 dilution, thus the titer of the virus is 64 HAU.  The last row was a 





In conclusion, the HA assay detects total virus particles of H1N1 propagated in 
MDCK cells, which confirmed the presence of virus after propagation and CPE that was 
seen as seen in Figure 9.  The assay did not detect virus particles in the propagation of 
H3N2 in tissue culture.  CPE was also not seen for this virus, confirming these negative 
results, as seen in Figure 10. 
Section 4: Titration of Virus using Tissue Culture Infectious Dose 50% Assay 
4.1 Methods 
A TCID50% assay was used with a MDCK-ATL cell line following established 
protocols22.  This assay determines the number of infectious viral particles per milliliter.  
Briefly, cells were seeded into a 96 well plate and allowed to attach for 24 hours. Viral 
dilutions were performed in viral dilution media of 1% Pen Strep 1ug/ml tosyl-
phenylalanyl-chloromethyl ketone (TPCK)-Treated Trypsin 1xDMEM.  Media was 
Figure 10: HA assay of H3N2 propagation in MDCK cells.  The first 
two rows contained dilutions of the media from the propagation.  The 
last row (F) was a negative control that just received buffer.  All results 
were negative, indicating that there was no virus present and H3N2 was 
not propagated using this method. 
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removed from each well and washed once with 100 µl of 1% Pen Strep HBSS.  One 
hundred microliters of viral dilutions were added down each column to inoculate the 
monolayer, seen in Table 2.  Plates were placed in the incubator at 37 degrees Celsius 5% 
CO2 for 45 minutes.  Once infection had occurred, 100 µl of DMEM-5%FCS was added 
to each well, and CPE was observed daily for four to seven days, or until 75% of the cells 
showed CPE.  Once completed, the Reed Muench Method for approximation of 
TCID50% was used to calculate the titer of the virus. 
 
Table 2: Example plate set up for a TCID50% Assay.  Each sample was diluted and 
added in a set of six across an entire plate.  Each column was a 1:10 dilution.  An 
additional plate for each experiment was done with no virus as a negative control. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-13 
B 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-13 
C 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-13 
D 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-13 
E 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-13 
F 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-13 
 
4.2 Results 
A TCID50% assay must be completed to determine if the viral particles are 
infectious.  Wells were checked daily and marked when CPE was visible.  For H1N1, CPE 
was typically seen by day 3.  The most concentrated virus dilutions showed CPE early, 
while the wells containing the most diluted virus (10-13) did not show CPE compared to 
the control, indicating that the virus was too dilute for productive infection in MDCK 
cells.  Figure 11 shows typical results of a TCID50% assay completed on the H1N1 virus 
propagated in MDCK cells.  CPE is clearly visible on day 3, indicating that infectious 





Once the results from the TCID50% assay have been obtained, the concentration 
of infectious particles can be determined.  The Reed Muench Method for approximation 
of TCID50% was used to calculate the titer of the virus22.  Briefly, the number of wells 
showing CPE for each dilution of virus was recorded daily.  After the assay was 
completed the percent infected at each dilution was calculated.  The proportional distance 
formula was used to calculate the log of the infectious dose for the virus.  This 
calculation was used in conjunction with the inoculate volume to determine the Infectious 
Dose 50% per unit volume for each virus.  Below is an example of how this is calculated. 
Figure 11: TCID50% results from propagation of H1N1 in MDCK cells.  CPE is clearly visible on day 3 
in wells incubated with the most concentrated virus, but absent in wells with more dilute virus (10-12) or 

















-2 6 6 0 6/6 100% 
-3 6 6 0 6/6 100% 
-4 4 4 2 4/6 66.7% 
-5 2 2 4 2/6 33.3% 
-6 0 0 6 0/6 0% 
-7 0 0 6 0/6 0% 
-8 0 0 6 0/6 0% 
-9 0 0 6 0/6 0% 
-10 0 0 6 0/6 0% 
-11 0 0 6 0/6 0% 
-12 0 0 6 0/6 0% 
-13 0 0 6 0/6 0% 
Proportional Distance Formula= [(% positive value >50%)-50%]/ [(% positive value 
>50%)-(% positive value <50%)] 
Log infectious dose50= (log dilution >50%) + (proportional distance x log dilution factor) 
Proportional Distance Formula= (66.7%-50%) / (66.7%-33.3%) = 0.5 
Log infectious dose50= -4+ (0.5x1) = -4.5 
Infectious dose 50 % titer: 104.5ID50/0.1ml or 10
5.5 ID50/ml 
Stock virus from the IRR was shipped with no reported concentration of total 
virus particles.  HA assay was used for the stock virus strains to determine the starting 
amount of virus that was used to propagate in MDCK cells, as described previously in 
this chapter.  A TCID50% assay was then completed to determine how many of these 
particles were infectious.  The ID50/ml was calculated for each virus stock.  Once 
determined, the plaque forming units per milliliter can be calculated by using the Poisson 
Distribution33.  Table 3 shows the titer determined by using these methods in the 
influenza stock vials from the IRR.  H3N2 had almost four times more total viral particles, 
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as seen by a HAU titer of a 128 versus a 32 in H1N1.  However, H3N2 has less infectious 
particles with a titer of 3.9x104 PFU/ml versus H1N1 titer of 3.9x10
5 PFU/ml.  This shows 
that the virus stocks of H3N2 had far more noninfectious particles then H1N1.   
Table 3: Concentration of virus in stock vials from the IRR, determined by HA assay and 
TCID50% assay 
Virus Stock  1 HAU ID50/ml PFU/ml 
H1N1 Stock Vial #1 1:32 105.5 ID50/ml 2.2 x105 PFU/ml 
H1N1 Stock Vial #2 1:32 105.75 ID50/ml 3.9x105 PFU/ml 
H3N2 Stock Vial #1 1:128 104.75 ID50/ml 3.9x104 PFU/ml 
H3N2 Stock Vial #2 1:128 104.6 ID50/ml 2.8x104 PFU/ml 
 
For use in future experiments, H1N1 virus was propagated several times to obtain 
a virus stock that could be frozen back.  Six flasks could be completed at once.  Flasks 
that had the same HA titer could be pooled together to minimize storage space.  Table 4 
shows the titer obtained by propagating H1N1 in several sequential propagations.   
 
Table 4: Concentration of virus from propagation of H1N1 in MDCK cells, determined by 
HA assay and TCID50% assay 
Virus Propagation  1 HAU ID50/ml PFU/ml 
Propagation #1 0.1 
HAU H1N1  
1:256 106.4 ID50/ml 1.76x106 PFU/ml 
Propagation #1 0.01 
HAU H1N1 
1:128 106.5 ID50/ml 2.2x106 PFU/ml 
Propagation #1 0.001 
HAU H1N1 
1:256 105.25 ID50/ml 1.2x105 PFU/ml 
Propagation #2 H1N1 
All Flasks 
1:64 106.66 ID50/ml 3.2x106 PFU/ml 
Propagation #3 H1N1 
Flasks 1, 2, 5, and 6 
1:64 106.65 ID50/ml 2.2x106 PFU/ml 
Propagation #3 H1N1 
Flasks 3 and 4 
1:32 106.34 ID50/ml 1.53x106 PFU/ml 
Propagation #4 H1N1 
Flasks 1, 3 and 6 
1:64 106.66 ID50/ml 3.2x106 PFU/ml 
Propagation #4 H1N1 
Flasks 2 and 4 
1:128 107.66 ID50/ml 3.2x107 PFU/ml 
Propagation #5 H1N1 
Flasks 1 and 2 
1:64 106.25 ID50/ml 1.2x106 PFU/ml 
Propagation #5 H1N1 
Flasks 4, 5, and 6 
1:128 106.25 ID50/ml 1.2x106 PFU/ml 
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In conclusion, the TCID50% assay was used to find the concentration of 
infectious particles in the stock vials of virus from the IRR, as well as in each of the 
propagations completed for H1N1 in tissue culture. The titer obtained on the stock vials 
showed that H1N1 had a higher titer of infectious particles (3.9x10
5 PFU/ml), than H3N2 
(3.9x104 PFU/ml).  The HA Assay showed that H3N2 had four times more total particles  
as seen in Table 3.  This shows that H3N2 stock had more defective particles than H1N1.  
The titer obtained for H1N1 propagated in MDCK cells after optimization ranged from 








Chapter 2: Blood Processing and Analysis of Subclasses of Antibodies 
 In human peripheral blood 48-70% are neutrophils (2.3-8.1x103/µl), 18-42% are 
lymphocytes (0.8-4.8x103/µl), 1-10% are monocytes (0.45-1.3x103/µl), 1-4% are 
eosinophils (0-0.4x103/µl), and 0-2% are basophils (0-0.1x103/µl)20.  We used Ficoll-
Hypaque to isolate the mononuclear cells (monocytes and lymphocytes) from whole 
blood.  This procedure separates the mononuclear cells from the red blood cells, 
neutrophils, and the plasma.  The majority of these cells are lymphocytes (~60%) and the 
minority are monocytes (~30%).  Lymphocytes consist of T cells and B cells.  Red Blood 
Cell Lysis can also be used which removes the red blood cells only leaving the 
neutrophils and the mononuclear cells.   
Section 1: Red Blood Cell Lysis 
1.1 Methods 
Whole blood was collected via venipuncture under approved IRB#4884 after 
obtaining informed consent.  Blood was collected into sterile EDTA Vacutainer tubes.  
Blood was stored using approved methods at 4 degrees Celsius before use.  Consent 
forms were securely maintained and donor samples labeled to insure anonymity.  Only 
demographics such as gender and age were used for labeling.  Proper personal protective 
equipment (PPE) was used at all times.  Fifteen milliliter falcon tubes were prepared.  
500 µl of whole blood was added to 10 mls of 1xRBC Lysis Buffer.  Tubes were inverted 
to mix and incubated at room temperature in the dark for 15 minutes.  Every 5 minutes 
the tubes were inverted and checked for turbidity.  After the incubation was complete, the 
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tubes were spun at 250xG for 5 minutes at room temperature.  The supernatant was 
decanted into a 20% bleach solution.  The cell pellet was dislodged and resuspended in 
10 mls of cell buffer (1% BSA 1mM EDTA 1xPBS).  The cells were spun at 250xG for 5 
minutes at room temperature.  After the wash, cells were resuspended in 3 mls of cell 
buffer. Then cells were counted using a hemocytometer according to published 
protocols20.  Once cells were counted, aliquots were taken for flow analysis. Each sample 
was incubated with the appropriate labeled antibodies and was prepared in a final volume 
of 100 µl in the cell buffer per manufacturer’s directions.  At least 300,000 cells were 
aliquoted for labeling, mixed with the labeled monoclonal antibodies and incubated on 
ice in the dark for 30 minutes. Then samples were washed twice with 400 µl of cell 
buffer and centrifuged at 400xG for 5 minutes at 4 degrees Celsius.  If a secondary 
antibody was needed (streptavidin) pellets were resuspended in 95 µl of cell buffer and 5 
µl of the flurophore conjugated to streptavidin.  These tubes were incubated and washed 
as previously described.  All samples prepared for flow cytometry analysis were pelleted 
after the last wash and resususpended in 200 µl of 1% paraformaldehyde (PFA) 1mM 
EDTA 1xPBS. Samples were analyzed using an Accuri C6 Flow Cytometer and CFlow 
Plus or FCS Express V3 software according to the manufacturer’s guidelines.   
The flow cytometer used in this thesis is a BD Accuri C6 Flow Cytometer System.  It 
contains two lasers, a blue (488nm), and a red (640nm).  It also has two light scatter 
detectors for side and forward scatter, and four fluorescence detectors.  The forward 
scatter detector indicates relative size of the cells, and the side scatter detector indicates 
complexity of the cells.  Relative forward and side scatter can differentiate between 
different cell types such as small lymphocytes versus larger and more granular monocytes 
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in a mononuclear cell sample. Different monoclonal antibodies can be purchased, that are 
conjugated to different flurophores.  The flurophore absorbs light from the lasers, then 
emits light that is detected by one of the four different detectors.  These detectors separate 
out the emitted light based on its wavelength.  Based on this data, a researcher can 
determine cell types and concentrations in each sample based on the antibody used which 
is conjugated to a particular flurophore38.  In this flow cytometer system, FL1 is the 
533/30 detector for Fluorescein Isothiocyanate (FITC), Phycoerythrin (PE) is detected by 
FL2 with a filter of 585/40, Phycoerythrin-Cy7 Tandem (PE-Cy7) is detected by FL3, 
with a filter of 670LP, and Allophycocyanin (APC) is detected by FL4 with a filter of 
675/2539.  For example, if Anti-Human CD19 APC is used for labeling in a mononuclear 
cell sample, a positive peak on filter FL4 will be detected.  The software assists in 
determining the percent of cells or events that are in the positive peak for FL4 in the 
entire sample, and by using a labeled monoclonal antibody, a specific cell populations 
can be identified.  For example cells positive for CD19 identifies B cell populations. 
1.1 Results 
Cells remaining after red blood cell lysis include the mononuclear cells and 
neutrophils from whole blood.  Figure 12 shows three cell populations (neutrophils, 
monocytes, and lymphocytes) based on side and forward scatter.  Neutrophils are the 
larger and more complex cells which make up the majority of the cell populations.  For 
this thesis project, purification of the monocytes was necessary.  Monocytes and 
neutrophils are both CD14+.  In order to use CD14 in a way to facilitate this separation, 






Section 2: Ficoll-Hypaque Separation 
2.1 Methods 
Ficoll-Hypaque (Hystopaque 1077 Sigma-Aldrich) isolation of mononuclear cells from 
whole blood, non Accuspin assisted.   
 Blood was stored using approved methods at 4 degrees Celsius before use.  Ficoll-
Hypaque separation was performed according to manufacturer specifications43.  After 
separation, cells were counted using the hemocytometer and labeled for flow analysis as 
described earlier.  Ficoll-Hypaque is a polymer that will separate out the mononuclear 
cells using a density gradient when centrifuged.  The red blood cells and neutrophils are 
found on the bottom of the tube, Ficoll-Hypaque composes the next clear layer, and a 
white buffy layer is above the Ficoll-Hypaque that contains the cells of interest, with the 
plasma at the top as seen in Figure 13. 
Figure 12: Side scatter and forward scatter of 
cells from a red blood cell lysis.  Three 
populations are shown, the lymphocytes, 
monocytes, and neutrophils.  The neutrophils are 




   
 
Ficoll-Hypaque (Hystopaque 1077 Sigma-Aldrich) isolation of mononuclear cells from 
whole blood, Accuspin assisted.   
 Whole blood was collected as described.  A 50 ml tube holds 15 mls of Ficoll-
Hypaque and 15 to 30 mls of undiluted blood.  The 15 ml tube holds 3 mls of Ficoll-
Hypaque and 3 to 6 mls of undiluted blood.   Ficoll-Hypaque was pipetted into the 
Accuspin tube, and spun for 30 seconds at 800xG to move the Ficoll-Hypaque to the 
lower chamber below the frit.  The Ficoll-Hypaque was then brought to room temperature 
on the bench while protected from light.  Whole blood was poured into the Accuspin tube 
along the side, and spun for 15 minutes at 800xG.  Once complete, the buffy layer was 
Figure 13: Before (left) and after 
(right) Ficoll-Hypaque separation of 
MNCs. After spinning MNCs are 
found above the Ficoll-Hypaque.  
Plasma is the top layer and red blood 
cells and neutrophils are at the bottom. 
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retrieved, washed, and counted as previously referenced.  The mononuclear cells are 




 Wright Stain technique was used to visualize white blood cell populations during 
experiments.  An aliquot of the cells was washed with 22% BSA, and then resuspended 
again in the 22% BSA.  Five µl of whole blood or cells in BSA was added to each slide, 
and a smear was made.  Once dried slides are dipped in the Wright Stain from the 
Thermo Scientific Modified Wright-Giemsa Stain Pack for 45 seconds, then dipped in the 
accompanying buffer solution containing phosphate salts for 30 seconds, then finally the 
Figure 14: MNC separation with 
Accuspin tube.  Mononuclear cells 
are above the Ficoll-Hypaque.  
Plasma takes up the top layer, and 
red blood cells and neutrophils make 
up the bottom. 
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wash containing methanol for 5 seconds.  A second type of Wright stain was obtained for 
use, Thermo Scientific Buffered Wright Stain.  These slides were first fixed in methanol 
for 30 seconds, and then dipped in the stain for 30-60 seconds.  Finally, the slides were 
rinsed in distilled water for 10 seconds and allowed to dry.  A monocyte and lymphocyte 




Ficoll-Hypaque facilitates isolation of the mononuclear cells, eliminating the 
contaminating neutrophils and enriches for a population of lymphocytes and monocytes 
only, as described in the methods section.  Below in Figure 16 normal mononuclear cell 
populations can be seen after Ficoll-Hypaque separation.  First, the side scatter and 
forward scatter is analyzed (graph 1 and 6), and the monocyte (P4) and lymphocyte (P3) 
populations are gated (graph 1) based on their size and complexity.  These populations 
are graphed as average forward scatter (FSCA) vs forward scatter heights (FSCH) to 
Figure 15: Monocyte (left) and lymphocyte (right), visualized 
using Wright Stain in whole blood 
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remove any doublets (graph 2 and 7).  The remaining events are analyzed for populations 
of interest.  Below, CD14+ cells represent monocytes (graph 3), CD3+ T cells (graph 4), 
CD4+ helper T cells, CD8+ cytotoxic T cells (graph 8), CD56+ natural killer cells (graph 
5), and CD19+ B cells (graphs 3 and 4).  These results are typical of a healthy donor. 
 
In summary, Ficoll-Hypaque separation was used to separate mononuclear cells 
from whole blood.  Flow cytometry was then used to study and quantify different cell 
populations like monocytes, T cells, and B cells.  As seen in Figure 16 and described in 
the first paragraph of section 2, T cells make up the majority of the mononuclear cells 
Figure 16: MNC populations after Ficoll-Hypaque separation.  Graphs 1-5 Donor A, Graphs 
6-8 Donor Q.  CD14 is a monocyte marker, CD3 is a T cell marker, CD19 is a B cell marker, 
CD4 is a T helper cell marker, and CD8 is a cytotoxic T cell marker.  Results represent typical 
cell populations in normal healthy donors. 
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after Ficoll-Hypaque separation, 50-60% of cells are CD3+.  In healthy individuals, 
CD4+ T cells make up the majority.  The monocytes constitute the next prevalent cell 
type, with approximately 30% of the cell population expressing CD14+.  B cells range 
from approximately 4-10% of all mononuclear cells and express CD19+.  Natural killer 
cells may also be present, and will be CD56+, but are usually less than 2% of the 
mononuclear cells and not usually seen.   
Section 3: B cell Subpopulations 
3.1 Results 
As described previously, our lab is interested in a B cell population known as the 
Marginal Zone B cells (MZBCs). MZBCs are IgDlow IgMhigh CD27+ CD19+.  These B 
cells are in the minority, making them difficult to analyze.  Labeling for the MZBCs was 
completed and analyzed using flow cytometry.  Data was analyzed as previously 
described.  Cells were gated for CD19+ cells (B cell marker, graph 3), then graphed with 
IgD vs IgM (graph 4).  The IgDlow IgMhigh cells were then analyzed for the CD27+ 
marker.  The MZBC population can be observed in Figure 17 below, graph 5.  Cells of 
several different healthy donors were analyzed for MZBCs, seen in Table 5.  Between 5-
10% of the mononuclear cells were B cells, which is in the known range described at the 




Table 5: MZBC analysis from different donors 
Donor Percent CD19+ of 
monocyte and lymphocyte 
gate 
Percent MZBCs of CD19+ 
cells 
Donor Q, 10-31-12 8.3% 8.6% 
Donor C, 11-6-12 7.9% 4.3% 
Donor A, 11-19-12 6.7% 5.1% 
Donor A, 3-12-14 5.4% 11.7% 
 
Once the flow cytometry analysis was performed for a normal healthy donor 
population, a sample was obtained from a patient with recurrent infections (IBC protocol 
Figure 17: MZBC analysis, Donor A 
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#211).  Preliminary data indicate that 2% of the mononuclear cells were B cells, less than 
half of what is seen in the healthy donors.  However the MZBCs from this patient, though 
low compared to healthy donors, was found to be normal relative to the total number of B 
cells present when compared to the healthy donors (3.5%).    
Along with MZBCs, other B cell populations can be analyzed using this method.  
As described in Figure 18, Naïve B cells shown in green are IgDhigh IgMlow CD27- (graph 
7).  Memory B cells shown in blue are CD27+ (graph 5). 
 
In summary, using the optimized method different populations of B cells, 
including MZBCs, Naïve B cells, and Memory B cells, can be identified and analyzed.  B 
Figure 18: B cell populations, Donor A 
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cells on average made up 4-10% of the mononuclear cells, with MZBCs making up 5-
11% of the B cell population.  This will be used for future experiments studying the 
interaction of B cells and infected DCs.   
Section 4: Enrichment of Monocytes from Mononuclear Cells 
4.1 Methods 
Monocytes can be differentiated into DCs in culture using interleukin 4 (IL-4) and 
granulocyte macrophage colony-stimulating factor (GM-CSF).  DCs are used in this 
thesis as a model for influenza virus infection in vitro.   
Mononuclear cells were separated from whole blood as described previously.  Ten 
microliters of Anti-Human CD14 Biotin (eBioscience) was diluted into 90 µl of cell 
buffer and kept on ice.  Mononuclear cells were pelleted and resuspended in the presence 
of the antibody and incubated on ice in the dark for 30 minutes.  After incubation cells 
were washed twice with 1 ml of labeling buffer at 400xG for 10 minutes at 4 degrees 
Celsius.  The pellet was then resuspended in 90 µl of labeling buffer and 10 µl of 
Miltenyi Biotec Streptavidin MicroBeads (10 µl of beads for 10^7 target cells).  The 
beads were thoroughly mixed with cells, and incubated on ice in the dark for 15 minutes.  
After the incubation period cells were washed with 1 ml of labeling buffer at 400xG for 
10 minutes at 4 degrees Celsius.  The final pellet was resuspended in 500 µl of cold 
separation buffer.  A prepared magnetic column apparatus and sterile MS column was 
removed from the -20 degree Celsius freezer.  The MS column for positive selection 
could hold a max of 2x108 total cells, see Figure 19 for an overview of this process.  The 
MS column was purged with 500ul of cold separation buffer.  Once purged, 500ul of 
cells with the microbeads was added to the column before it went dry, and allowed to 
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flow though into a 1.5 ml tube.  The cell prep was passed though the column twice.  
Subsequently, 500 µl of additional cold separation buffer was added to rinse the column, 
and repeated two more times.  The flow through volume collected from the column was 
the unlabeled cell fraction.  The column was then removed from the magnetic field, and 
one milliliter of cold separation buffer was added to the column and quickly plunged.  
This process removed all of the labeled cells (CD14+) from the column.  This cell 
population was then collected in another 1.5 ml tube.  Cells were counted and labeled as 
described above.  Antibodies used included: CD14, CD3, CD56, CD19, CD80, CD11c, 
and HLA-DR (MHC Class II).    
 




Figure 20 shows the flow data of the separation at each step.  Total mononuclear 
cells were placed in the column with CD14 labeled cells attached to magnetic beads.  The 
passed cells come out in step one.  In step two, the bound cells were plunged out.  A 
greater number of cells are seen in gate P7, the monocyte gate, in the flow data of this 
step.  The flow data indicates that the magnetic bead separation enriches for the CD14 
cell population.    
 
 
Additional cell labeling was performed to determine the purity of the separation 
and to identify any contamination that may be present.  A typical example of this is seen 
in Figure 21.  Analysis was completed as previously described, gating to remove any 
doublets. Labeling for flow cytometry was done for CD14 (monocytes), CD3 (T cells), 
CD19 (B cells), and CD56 (natural killer cells) to verify purification.  A purity as high as 




95% was achieved of CD14+ cells, seen in graph 3 which represents CD14+ cells in the 
column bound population.  These monocytes would be used for future experiments, and 
differentiated into DCs, described later.  There is less than 1% contamination of B cells 
(CD19+ in graph 3), and about 1.6 % contamination of T cells (CD3+, graph 6).  
Labeling for CD11c (human pan DC marker) was used as a negative control before the 
monocytes were put into DC culture (graph 7).  The presence of CD11c after culture was 





In conclusion, the flow cytometry data in Figure 21 shows that using this method 
monocytes could be successfully separated from the mononuclear cells with high yield 
Figure 21: Purification analysis of monocytes from separation.  95% purity achieved, seen in 




and purity of up to 95%.  These cells were added to conditioned medium to induce 
differentiation to DC. These DCs are used as an in vitro model for influenza infection.   
Section 5: B cell Separation from Mononuclear Cells  
5.1 Methods 
To study the interaction of B cells and infected DCs in vitro, a protocol was 
optimized to separate B cells (about 10% of mononuclear cells) with high purity and 
yield. 
Mononuclear cells were isolated from whole blood using Accuspin tubes as 
described previously.  After counting, cells were resuspended to a concentration not 
exceeding 108 cells per milliliter in Dynabead buffer. Five microliters of Anti-Human 
CD3 Biotin (eBioscience) were added to the cells in buffer.  These cells were placed on 
ice, protected from light and incubated in a shaker set at 100RPM for 30 minutes.  After 
incubation, the cells were washed with 1 ml of Dynabead buffer for 8 minutes at 4 
degrees Celsius at 400xG.  After the wash, cells were resuspended in 1 ml of Dynabead 
buffer.  Life Technologies Dynabead Biotin Binders (CAT# 11047) were prepared 
according to the manufacturers specifications.  There were 4x108 beads per milliliter and 
was adjusted after each depletion to a concentration of 5 beads per target cell for the 
depletion.  Once the volume of beads was calculated, the volume was removed from the 
stock bottle and placed in a small tube inside the Dynabead magnet for 1 minute.  The 
supernatant was discarded, and the beads were resuspended in the original volume with 
Dynabead buffer.  Once the beads were prepared, they were added to the washed cells.  
One milliliter of Dynabead buffer was added to limit the trapping of unbound cells.  
These cells were placed on ice, protected from light and incubated in a shaker set at 
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100RPM for 30 minutes.  After incubation, the tube was placed in the magnet for 3 
minutes, and the supernatant was removed and transferred to a new tube on ice.  The 
beads were resuspended in 1 ml of Dynabead buffer.  The magnetic depletion step above 
was then repeated.  After completed, the beads were resuspended in 1 ml of Dynabead 
buffer and kept on ice.  Aliquots of each step were taken for photographs, Wright Stain, 
and flow analysis.  Cells in each step, including those bound to beads, were counted using 
a hemocytometer.  A second depletion was completed with 5ul of Anti-Human CD3 
Biotin (eBioscience) and 5 µl of Anti-Human CD14 Biotin (eBioscience) used together.  
A third depletion was completed using 5 µl of Anti-Human CD14 Biotin (eBioscience). 
5.2 Results 
After three depletions CD19+ cells were separated from MNCs.  As seen in 
Figure 22, beads appear as metallic balls around cells.  They can be easily seen bound to 
beads in clumps in the bound population.  In the population that passed through the 
magnet, no beads can be seen.  Wright Stain was also used to determine visually the cell 
populations that were present.  Wright staining facilitates differentiation between 
lymphocytes and monocytes, and this provides information about the cell populations that 
are present.  This stain, however, cannot differentiate between different lymphocyte 
populations.  In order to determine the purity of the lymphocyte populations, flow 





In Figure 23, typical flow cytometry results are shown of B cell depletion.  As 
described previously, the cells are gated to remove doublets (graph 3).  Graph 1 and 2 
show the side and forward scatter from the flow analysis.  After three depletions, the 
lymphocyte gate (P5) contains a higher percentage of cells compared to before depletion, 
indicating that a lymphocyte population is being purified.  In graphs 7, 8, and 9 after the 
depletion is completed CD3 disappears and only a small amount of CD14 remains 
(2.3%).  The percentage of CD19+ cells increases from 6 to 17%. 
 
Figure 22: B cell separation using Dynabeads.  The beads appear colored around 
cells.  The cells that passed through the magnet do not contain any beads, but in the 





The flow cytometry data indicates that the B cells were purified, but there were 
many unlabeled cells in the population.  This was found to be typical of these 
experiments, as it appears that 80% of the mononuclear cells were unlabeled.  Markers to 
detect all mononuclear cells are used for labeling, so no cell types are missing.  Wright 
Figure 23: Flow cytometry analysis of MNCs depleted of CD3 and CD14 
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stain analysis of the above experiment showed 96% lymphocytes and 4% monocytes.  
This microscopic examination confirms the flow data, indicating that there is little 
monocyte contamination, and that the majority of the cells are lymphocytes.  After many 
replicates of the depletion with the same results, these unlabeled cells can be attributed to 
debris, because positive and negative controls show that the antibodies used to label are 
fully functional, and the Wright stain microscopic examinations confirm the results.  
Taking this into account, the true purity of the CD19+ cells is 88% for this experiment, 
which is what is typically seen using this protocol.  The largest concern for this future in 
vitro experiment is presence of contaminating T cells which could affect data 
interpretation.  However, T cells were almost completely depleted whereas little 
monocyte contamination was noticed (11.7%).   
In conclusion, the data presented in Figure 23 shows that this method can be used 
to obtain a population of CD19+ cells for future experiments with high yield (88% 
purity).  Isolation of this B cell population was done by negative selection.  Hence 
magnetic beads were not used to positively select for these cells since manipulation could 
cause this cell population to become activated, adversely affecting results.   
Section 6: Antibody Assay using Hemagglutination Inhibition 
6.1 Methods 
Volunteer serum was collected before influenza vaccination and 30 days post 
influenza vaccination.  It was necessary to confirm the presence of influenza specific 
antibodies in this serum before and after vaccination because this serum would be used in 
future experiments to optimize the influenza specific ELISA.  A white 96 well round 
bottom plate was used to make viral dilutions. Fifty microliters of H1N1 or H3N2 virus 
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dilution were added to each well.  Two HAU of influenza were added to each well to 
confirm a positive result would occur.  Negative control wells received 1x PBS with no 
virus.  Fifty microliters of pre and post flu vaccine serum from the volunteers were added 
to the first well (1:2 dilution).  A multichannel pipette was used to mix the well 5 times.  
Two fold serum dilutions were performed, mixing between each step.  The positive 
control wells with virus did not receive serum.  The plate was covered and incubated at 4 
degrees Celsius for 20 minutes.  After the incubation, 50 µl of a 1% TRBC solution in 
Alsever’s were added to each well, and the plate incubated for an additional 45 minutes. 
Hemagglutination is inhibited when specific HA antibodies are present in the 
sample, precluding the viral HA to agglutinate red blood cells.  Figure 24 demonstrates 
the principle of this assay.  The highest dilution of the serum that prevents 
hemagglutination is the HA titer of the serum.  If the serum contained no antibodies 
against the virus strain, then hemagglutination is expected in all wells. 
 
 
Figure 24: Antibody inhibition assay.  If enough influenza 
specific antibodies are present, they bind influenza particles, and 




The results of the antibody inhibition assay can be seen in Figure 25 below.  The 
serum contained influenza specific antibodies for both H1N1 and H3N2, showing that it 
could be used to optimize later assays.  The influenza specific antibody titer was lower in 
the pre vaccination then the post vaccination for both viral strains.  This is expected, 
because vaccination with the seasonal influenza vaccine should increase the influenza 
specific antibody titer.  It is expected to see some antibodies against influenza to be 
present before vaccination.  This is because influenza virus is very common, and 
individuals are exposed to it on a regular basis, which would cause them to produce some 
antibodies against it even though they did not develop an active infection.   
 1 2 3 4 5 6 7 8 9 10 11 12 
H1N1 
Pre Vac 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 
H1N1 
Post Vac 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 
H3N2 
Pre Vac 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 
H3N2 
Post Vac 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 
Positive 
Control  
H1N1 H1N1 H1N1 H1N1 H1N1 H1N1 H3N2 H3N2 H3N2 H3N2 H3N2 H3N2 
Negative 
Control 
- - - - - - - - - - - - 
 
In summary, the assay showed that influenza-specific antibodies to both H1N1 and 
H3N2 were present in the specimen.  The amount of these antibodies increased after 
Figure 25: Antibody inhibition assay results from donor S 
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vaccination with the inactivated influenza vaccine, as expected. This serum was used to 
optimize assays for the determination of subclasses of influenza specific antibodies.    
Section 7: Detection of Subclasses of Antibodies 
7.1 Methods 
 Future studies will involve the interaction of B cells and infected DCs in vitro, so 
a protocol was optimized to separate un-manipulated B cells (about 10% of mononuclear 
cells) with high purity and yield.  This was accomplished as described in Chapter 2, 5.2. 
Included in this study, the subclass of antibodies secreted needs to be analyzed.  These 
antibodies may be secreted in vitro in much lower concentration than normal, so highly 
sensitive Enzyme Linked Immunosorbent Assays (ELISAs) were developed.  See 
Appendix C for a list of the different Antibodies used for each ELISA method.   
Enzyme Linked Immunosorbent Assay (ELISA) Method #1: Pierce Goat Anti-
Human IgG Kappa and Pierce Goat Anti-Human IgG Lambda Sensitized, BD Pharmigen 






For the detection of IgGs and associated light chains in human serum, primary 
antibody was diluted into bicarbonate buffer.  Pierce Goat Anti-Human IgG Lambda or 
Pierce Goat Anti-Human IgG Kappa was diluted 1:40 in bicarbonate buffer, and 50 µl 
was added to each assigned well in a Thermo Immulon 2HB 96 well flat bottom ELISA 
plate.  The plate was incubated at room temperature for 1 hour covered.  After incubation, 
the plate was then washed three times with 100 µl of 1xPBS.  To block for non-specific 
binding, 200 µl of blocking buffer (5% nonfat dry milk 0.1% Tween 1XPBS) was added 
to each well, and incubated covered overnight at 4 degrees Celsius.  The next morning 
the wells were washed three times with 100 µl of 1xPBS 0.1% Tween.  Fifty microliters 
of the sera (standard or unknown serum dilutions) diluted in blocking buffer was added to 
the assigned wells.  Standard serum samples used are as follows; Sigma IgG1 Kappa 
from human myeloma plasma (CAT# I5154 Lot# 081M6276 1.13mg/ml), Sigma IgG1 
Figure 26: ELISA method #1 overview 
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Lambda from human myeloma plasma (CAT# I5029 Lot# 091M6298 1.18 mg/ml), 
Sigma IgG2 Kappa from human myeloma plasma (CAT# I5404 Lot#067K6026 
1.1mg/ml), Sigma IgG2 Lambda from human myeloma plasma (CAT# I5279 
Lot#061M6247 1.00mg/ml).  Sera dilutions were incubated for 1 hour covered at room 
temperature.  After incubation, the wells were washed three times with 100 µl of 1xPBS 
0.1% Tween.  The secondary antibody was added to assigned wells diluted in blocking 
buffer.  Secondary antibodies are as follows; BD Pharmigen Biotin Mouse Anti-Human 
IgG, BD Pharmigen Biotin Mouse Anti-Human IgG1, BD Pharmigen Biotin Mouse Anti-
Human IgG2, Abcam Mouse Anti-Human IgG3 HRPeroxidase, BD Pharmigen Mouse 
Anti-Human IgG4, and Pierce Goat Anti-Human IgG Peroxidase.  Secondary antibody 
was incubated at room temperature for 1 hour covered.  After the incubation time was 
completed, the wells were washed three times with 1xPBS 0.1% Tween.  Fifty microliters 
of a 1:1000 dilution in 1xPBS of the detector Thermo Scientific ImmunoPure 
Streptavidin Horseradish Peroxidase (CAT# 21126 Lot: MD157646) was added if 
required by the secondary antibody, and incubated at room temperature for 1 hour 
covered.  After this final incubation, the wells were washed three times with 1xPBS 0.1% 
Tween, and 50 µl of 3, 3’, 5, 5’ Tetramethyl Benzidine (1xTMB) substrate was added.  
The reaction was allowed to continue until a blue color was seen, monitoring the control 
wells for background which reacted in approximately 10-15 minutes.  During this time, 
the plate was placed in the 37 degree Celsius incubator for one minute, and checked each 
minute after.  After completion, the reaction was stopped by adding 1M H2SO4, and read 
at 450nm with a Bio-Tek Instruments Automated Microplate Reader ELx800.  See Figure 
26 for an overview of the described protocol.   
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ELISA Method #2: BD Pharmigen Purified Mouse Anti-Human IgGs Sensitized, 
BD Pharmigen Biotin Mouse Anti-Human Ig Kappa Light Chain and Lambda light chain 
secondary. 
 
 For the detection of IgGs and associated light chains in human serum, primary 
antibody was diluted in carbonate buffer.  BD Pharmigen Purified Mouse Anti-Human 
IgG, BD Pharmigen Purified Mouse Anti-Human IgG1, or BD Pharmigen Purified 
Mouse Anti-Human IgG2 were diluted in carbonate buffer and 50 µl of the dilution was 
added to the assigned wells on a Thermo Immulon 2HB 96 well flat bottom plate.  Assay 
was completed as previously described.  Secondary antibodies are as follows; BD 
Pharmigen Biotin Mouse Anti-Human Ig Kappa Light C, or BD Pharmigen Biotin Mouse 
Anti-Human Ig Lambda Light Chain.  Figure 27 shows an overview of the described 
protocol.    
 In order to standardize the concentrations of IgGs in serum from a single 
volunteer, a Human IgG Subclass Profile kit was purchased from Invitrogen (CAT# 




991000).  This kit was used to determine the amount of IgG1, IgG2, IgG3, and IgG4 in a 
single volunteer, so that serum could be used as a standard for unknowns in the future.  
The kit was used according to the specifications by the manufacturer, and following the 
protocol it was determined that the volunteer had 6.76 mg/ml of IgG1, 3.27 mg/ml of 
IgG2, 0.82 mg/ml of IgG3, and 0.98 mg/ml of IgG4, all within the normal ranges for the 
volunteers age.   
ELISA Method #3: IRR Influenza A H1 and H3 Control antigen sensitized, BD 
Pharmigen Biotin Mouse Anti-Human IgGs and IgM secondary. 
 
  
For the detection of IgGs and IgM specific to H1 and H3 influenza antigens, 
antigen was diluted into bicarbonate buffer.  Influenza Reagent Resource (IRR) Influenza 
A (H1) pdm09 Control Antigen or IRR Influenza A (H3) were diluted 1:50 in bicarbonate 
buffer, and 50 µl was added to each assigned well in a Thermo Immulon 2HB 96 well flat 
bottom plate.  This assay was completed as previously described, with unknown samples 
diluted in DMEM-5%FCS.  Secondary antibodies included: BD Pharmigen Biotin Mouse 




Anti-Human IgG, BD Pharmigen Biotin Mouse Anti-Human IgG1, BD Pharmigen Biotin 
Mouse Anti-Human IgG2, Abcam Mouse Anti-Human IgG3 HRPeroxidase, BD 
Pharmigen Biotin Mouse Anti-Human IgG4 and BD Pharmigen Biotin Mouse Anti-
Human IgM.  See Figure 28 for a summary of the described protocol.   
 As a positive and negative control for the influenza ELISA, a combination of the 
H1 and H3 antigens described were used in conjunction with IRR Mouse Monoclonal 
Antibody Influenza Type A H3, IRR Mouse Monoclonal Antibody Influenza Type A H1 
pdm09, and IRR Mouse Monoclonal Antibody Influenza A pool at a 1:50 dilution with a 
detector of Thermo Scientific Stabilized Peroxidase Conjugated Goat Anti-Mouse H+L 
IgG at a 1:500 dilution.   
 All results were expressed as the average of a set of triplicates.  Results were 
considered significant above background if the average of the Optical Density (OD) was 
three times the standard deviation of the negative control group, as described by John 
Crowther in The Elisa Guidebook34. 
 All experiments were completed with positive and negative controls of each step 
to verify that each antibody or detector was working, and there was no cross reactivity 
between different steps in the sandwich ELISA.  Background for all ELISAs was an 
average OD of 0.05-0.06.  Unless otherwise indicated, graphs of ODs are represented as 
the geometric mean of the triplicate with standard deviation bars.   
The sera collected from volunteers are described in the subject section. 
7.2 Results 
All ELISAs were optimized by completing serial dilutions of the different 
antibodies or detectors.  These dilutions were tested with the system, and the dilution that 
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gave the brightest color change was chosen.  The optimized working dilution of each 
ingredient was described in the methods section earlier in this section.   
Enzyme Linked Immunosorbent Assay (ELISA) Method #1: Pierce Goat Anti-
Human IgG Kappa and Pierce Goat Anti-Human IgG Lambda Sensitized, BD Pharmigen 
Biotin Mouse Anti-Human IgGs secondary. 
To determine concentrations of IgGs in an unknown serum (Serum A), the 
Human IgG Subclass Profile Kit (CAT# 991000 Lot# 844404) was purchased from 
Invitrogen, and was followed according to the manufacturer’s directions.  Other standards 
were used also, as described earlier in this chapter.  To determine the unknown quantities, 
the standard was plotted with the average OD and known concentration of the antibody.  
The unknown sera were tested in parallel and plotted.  The unknown OD was used in the 
linear equation for the slope of the best fit line of the standard.  This was used to quantify 
the unknown concentration of IgG subclasses.  This unknown concentration was then 
multiplied by the dilution factor taking into account the volume that was added to the 
well.  For example, in Figure 29, the standard and unknown graphs for IgG1 are shown.  
In Table 6, the concentrations determined by this method are shown.   
 




Table 6: Quantification of IgGs in serum using Invitrogen Kit 




6.6 mg/ml 3.3 mg/ml 0.8 mg/ml 0.98 mg/ml 
Normal Range 
(mg/ml) 
5-12 mg/ml 2-6 mg/ml 0.5-1 mg/ml 0.2-1 mg/ml 
 
Ten different sera from volunteers as well as a mixed serum standard from 
Biorbyt were used in this ELISA to determine reproducibility with IgG1 and IgG2.  
Assays for IgG3 and IgG4 were not performed for these sera because the subclasses of 
interest in this project were IgG1 and IgG2.   The data shown in Figures 30 and 31 
demonstrate that the system is optimized and functional using sera from normal healthy 


















A sample was obtained from a patient with recurrent infections (IBC protocol 
#211), as described previously as donor L.  This patient serum sample was assayed using   
the optimized system.  Preliminary data is shown in Figure 32.  The IgG2 from this 
patient does not appear to be detectable with the kappa light chain.  
 





The Purified Myeloma Standards listed earlier in this chapter had a known 
concentration value with at least 95% purity.  These were diluted and used to determine 
the sensitivity of the optimized ELISA using the methods described earlier.  Table 7 
shows the known concentrations of the Myeloma Standards that were used for both 
ELISA method #1 and #2 described below.  The sensitivity of this ELISA and the second 
ELISA type is shown in Table 8. 









1.13 mg/ml 1.18 mg/ml 1.1 mg/ml 1.00 mg/ml 
 
 In summary, this ELISA was optimized to detect total IgG, along with subclasses 
IgG1, IgG2, IgG3, and IgG4 and the associated light chains of kappa and lambda in 
human serum from several different donors.  Capture antibodies of Pierce Goat Anti-
Figure 32: Preliminary data from donor L 
61 
 
Human IgG Lambda or Pierce Goat Anti-Human IgG Kappa were used along with 
secondary antibodies of BD Pharmigen Biotin Mouse Anti-Human IgG, IgG1, IgG2, and 
IgG4 along with Abcam Mouse Anti-Human IgG3 HRPeroxidase.  
ELISA Method #2: BD Pharmigen Purified Mouse Anti-Human IgGs Sensitized, 
BD Pharmigen Biotin Mouse Anti-Human Ig Kappa Light Chain and Lambda Light 
Chain secondary. 
As in ELISA method #1, multiple donors were used to test the optimization of 
this second ELISA method, and be sure that the system was working across multiple 
samples.  The results of these experiments can be seen below in Figures 33 and 34. 
 





In summary, this ELISA was optimized to detect total IgG, along with subclasses 
IgG1, IgG2, IgG3, and IgG4 and the associated light chains of kappa and lambda in 
human serum from several different donors.  Capture antibodies of .BD Pharmigen 
Purified Mouse Anti-Human IgG, IgG1, and IgG2 were used along with secondary 
antibodies of BD Pharmigen Biotin Mouse Anti-Human Ig Kappa Light chain and 
Lambda Light chain, as described previously.   
As described previously in this chapter and shown in Table 7, the standards were 
diluted to determine the sensitivity of the different ELISA methods.  The sensitivities 
Figure 34: ELISA method #2 multiple serums 
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with different combinations of capture antibody or antigen and detectors are shown in 
Table 8.  The ELISA methods developed are very sensitive, and can detect nanogram 
amounts of antibodies.  This sensitivity may prove helpful when detecting antibodies in 
the future co-culture studies referenced in the purpose section.    
Table 8: Sensitivities of different methods 
Capture Detector Detects at 










































































17.41 ng* Biorbyt Standard 
 
As stated in the Purpose and Specific Aims section, the future goal of this 
research is to understand the interaction between different populations of B cells in the 
presence of DCs loaded with inactivated virus as well as infected DCs in the antibody 
response to influenza infection in vitro.  The intent of this study will be to co-culture 
MZBCs with Influenza A-infected DCs, or B cells with inactivated Influenza A DCs and 
compare with mock-infected controls.  Antibody isotypes and IgG subclasses will be 
analyzed.  These antibodies may be secreted in a concentration much lower than normal 
in vitro, so highly sensitive ELISAs were developed to determine if there was a detection 
system that would produce results before this future work could begin.  Results in Table 8 
demonstrate adequate sensitivity for future assays. 
 In summary, the optimized ELISAS are highly sensitive, which is important for 
future work with subclasses of antibodies that may be in lower concentrations then what 
is normally found in circulation.        
ELISA Method #3: IRR Influenza A H1 and H3 Control antigen sensitized, BD 
Pharmigen Biotin Mouse Anti-Human IgGs and IgM detector 
This ELISA was optimized to detect influenza specific antibodies.  We 
hypothesize that these antibodies will be secreted in the co-culture of influenza infected 
DCs and separated B cells.  
Pre flu vaccine serum and 30 days post flu vaccine serum was used from three 
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different volunteers (A, I, and S) to make sure the optimized ELISA for influenza specific 
antibodies was working.  First, total IgG1 and IgG2 for the volunteers was quantified 
with the standard using methods described previously.  The standard was used as a 
control, to determine that the volunteers had total IgG1 and IgG2 present, before looking 
for influenza specific antibodies of those subclasses.  The known values determined using 
this method are shown in Table 9.  All values are in the normal reported range, as 
expected. Data can be seen in Figures 35-37.   
Table 9: Quantification of IgGs in donors 
Quantification using ELISA 




Serum A 4.16 7.04 IgG1: 5-12 
IgG2 2-6 
IgG1: 5.57 
IgG2: 3.08 Serum I 9.05 2.9 
Serum S 6.23 5.09 
 
 












Once total antibodies for each donor was quantified, influenza specific antibodies 
in the optimized ELISA system were determined for two of the donors.    The first donor, 
donor A shown in Figure 38 did not have a difference in influenza specific antibodies 
between pre and post flu vaccine.  Also, IgG2 antibodies to H1 were highly variable and 
could not be measured.  Interestingly, this volunteer was actively exposed to the virus in 
a controlled environment during the research process and thus chronic exposure to this 
virus could influence the appearance of influenza antibodies after vaccination. 
 






To insure that the assays were properly working, another volunteer serum pre and 
post flu vaccination was used in the optimized system who had not had exposure to the 
Figure 38: Influenza specific antibodies donor A 
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Influenza A virus.  Serum S showed a difference in the concentration of influenza 
specific antibodies after vaccination with the seasonal flu vaccine, seen in Figure 39.  
IgG2 for this individual was undetectable as seen with the previous donor.  At 30 days 
post influenza vaccine, the majority of the influenza antibodies should be of the IgG1 
isotype because immunologic memory has developed, as described in the introduction.   
 
 





Serum from volunteer S was also used to determine presence of influenza specific 
(H1 or H3) antibodies of the IgG3 and IgG4 subclasses and the IgM isotype.   Figure 40 
shows the data for this experiment.  Anti-IgG3 was detectable above background.  
However, Anti-IgG4 was not detectable, as expected because it is the antibody in lowest 
concentration. 
 
In conclusion, this ELISA was optimized to detect H1 and H3 antigen specific 
antibodies for total IgG, IgM, and the subclasses IgG1, IgG2, IgG3, and IgG4.  There was 
an increase in influenza specific antibodies after vaccination seen in IgG1.







Chapter 3: Dendritic Cell Production and Infection 
Section 1: Differentiation of Monocytes to Dendritic Cells 
1.1 Methods 
Purified CD14+ cells were counted and split into 12 wells of a 12-well tissue 
culture plate.  1 ml of 2x DC media (see appendix for recipe) and 6.25x104 cells per well.  
The plate lid was secured, and placed in an incubator at 37 degrees Celsius 5% CO2.  
Attachment of monocytes to the bottom of each well was observed.  Fresh 2x DC media 
was made and media was changed in each well on day 3.  The plates were checked for 
attached and unattached cells before and after media change, and put back into the 
incubator.  Day 7 after the cells were plated the culture was prepared for H1N1 viral 
infection.  Each well was washed three times with 1 ml of DMEM-10%FCS.  The cells 
were counted using a hemocytometer as described.  Flow analysis was completed as 
previously described.  The switch from CD14 to CD11c and CD80 indicated transition 
from monocyte to DC.  DCs can also be detected by observing attached monocytes vs 
unattached DCs. 
1.2 Results 
Cytokine concentration in the DC media had to be initially optimized, to 
determine the concentration of GMCSF and IL-4 to be used to get the highest yield of 
DCs.  A 1x and 2x DC media solution was made and tested.  Cells were analyzed using 
flow cytometry as previously described, and labeled for CD11c, a DC marker.  Typical 
results are shown below in Figure 41.  A 2x DC media solution was determined to be 
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optimal, because of the increase in CD11c compared to control with no cytokines and 1x 
media.  2x DC media was 94% CD11c+, where 1x was 91% CD11c+.  The majority of 
the cells are positive for CD11c.  Compared with the monocytes separated before culture 
in chapter two, all cells were negative for CD11c which demonstrates that culture 
conditions enhanced differentiation of the monocytes to DCs.  
 
Photographs of cells in the DC culture were taken at the beginning of culture, 
before and after media change on day 3, and on the last day of culture.  Figure 42 below 
shows typical cells in these different stages of culture.  The first photographs taken 15 
hours after culture show cells that have attached to the bottom of the plate.  This is 
expected because they cells are monocytes, which are adherent.  On day 3, the media was 
Figure 41: DC production, Donor A, 11-13-12 M8: Control: 65.84% 1x DC media: 
91.05% 2x DC media: 94.15%.  2x DC media had a higher percent positive for 




changed, and cells are seen still attached.  This shows that cells are not washed away at 
this time point.  This is expected because the monocytes are not DCs yet and should still 
be attached to the plate.  The last photographs show the cells at day 7 of the culture 
before they are washed and pooled for infection. 
 
 In conclusion, the DC media was optimized to produce monocyte derived DCs.  
This was confirmed by analyzing the presence of CD11c, a marker for DCs45, after 7 
days of culture as seen in Figure 41. 
Figure 42: Cells in DC culture 
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Section 2: Infection of Dendritic cells with A/California/07/2009 (H1N1pdm)   
2.1 Methods 
Influenza virus was heat inactivated using established protocols35.  To confirm the 
virus was inactivated, 1:10 dilutions of inactivated influenza were seeded onto a prepared 
96 well tissue culture plates containing MDCK cells at confluence in Influenza Virus 
Growth Medium.  The TCID50% assay was completed, and wells were checked daily for 
CPE.  CPE was not observed in the wells containing inactivated virus, which confirmed 
the heat inactivation was successful.   
Monocyte Derived Dendritic Cells were produced as previously described. DCs 
were collected from the supernatant of the culture into a 15 ml tube, and wells were 
washed three times with 1 ml of DMEM-5%FCS.  The contents were pooled together, 
and DCs were counted as previously described.  Based on cell number, DCs were split 
into separate tubes.  Ten MOI of H1N1 virus was used (infectious and heat inactivated), as 
well as one tube for mock infection that did receive any virus.  The cells were pelleted by 
spinning at 250xG for 10 minutes, and the pellet was resuspended in the assigned 
concentration of virus in 5 mls of 1x DMEM containing 2ug/ml of TPCK-Treated 
Trypsin with no FCS.  Tubes were gently agitated, and placed in a 37 degree Celsius 
water bath for 40 minutes, mixing every 10 minutes during incubation.  After the 
incubation, the tubes were transferred to the tissue culture incubator at 37 degrees Celsius 
5% CO2, with the lid slightly cracked for gas exchange with the tube rested at an angle.  
The tubes were incubated for 4 hours to allow for infection of the DCs.  After incubation, 
3 mls of DMEM-10%FCS was added to each tube, and the DCs in each treatment were 
pelleted by spinning at 250xG for 10 minutes.  These cells were resuspended into 1 ml of 
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DMEM-10%FCS and washed again.  Cells were counted using established protocols, and 
cells were separated for flow analysis. 
2.2 Results 
A TCID50% Assay was completed as previously described in Chapter 1 using 
heat-inactivated virus.  No CPE was observed in any of the wells compared with the 
controls, as seen in Figure 43.  This confirmed that the virus had been heat-inactivated 
following the procedure.   
 
Section 2: Detection of Markers 
2.1 Methods 
Markers used for flow analysis were determined to work by labeling of total 
MNCs, following previously described protocols.  Activation makers were tested in the 
same way on MNCs activated by lipopolysaccharide (LPS) to determine that the 
monoclonal antibodies worked as expected.  Briefly, MNCs after separation were 
resuspended in 0.1 µg/ml LPS, 1 µg/ml, or 10 µg/ml of LPS in 1x DMEM.  Tubes were 
incubated for 2 hours at 37 degrees Celsius 5% CO2 with the lids cracked to allow for gas 
Figure 43: TCID50% Results of heat inactivated H1N1.  No CPE seen, which confirms 
that virus were inactivated. 
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exchange.  After incubation, the cells were washed by spinning at 250xG for 10 minutes 
and the pellet was resuspended for labeling and flow analysis.  Monoclonal antibody 
flurophore conjugates to CD14, CD83, CD11c, CD40, CD80, and HLA-DR were used.   
Labeling of infected and mock infected DCs for flow analysis was completed as 
previously described. Specifically monoclonal antibody flurophore conjugates to CD40, 
CD80, CD11c, and HLA-DR were used. 
2.2 Results 
The LPS activation was analyzed using flow cytometry.  The results are seen 
below in Figure 44.  A percentage of MNCs became larger and more granular, as seen in 
P6 gate on the side and forward scatter graphs.  This indicated that cells were activated.  
Activation markers CD40 and HLA-DR increased in the LPS activated cells compared to 
the control, and also increased in brightness as indicated in Figure 44.  An increase in 
brightness shows that there is more of that marker being expressed on the cell surface.  If 
a cell becomes activated, it would be expected that more activation markers would be 
expressed.  This experiment showed the antibodies were working as expected and could 




Figure 44: LPS stimulation of DCs.  Cells were activated successfully by LPS, as seen by the 
increase of cells in gate P6 (the activated gate), that contains cells that are larger and more 




Infectious and heat inactivated virus were used in conjunction with mock infected 
controls to infect monocyte derived DCs.  This infection was completed in independent 
replicates, and typical results can be seen in Figure 45 below.   
 
 
Figure 45 of the DC infection shows that the majority of the cells in all of the 
treatments were positive for activation markers and DC markers.  To determine if there 
was a difference between any of the treatments the brightness of the markers was 
Figure 45: Infection of DC with 10 MOI of infectious and heat-inactivated virus corresponding 
to 10 MOI of infectious virus and mock infected controls. 
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analyzed.  There was no observable difference between the brightness of markers for 
CD80, CD40, and HLA-DR. However the brightness of CD11c appeared to increase.   
Using Welch’s t test and the z distribution (z distribution is used because the number of 
samples in each treatment is larger than 1000), the differences in the brightness of 
different markers can be compared to the control mock infected DCs and determined if 
the difference is significant at different confidence intervals. Below in Table 10, the data 
from each of the infection experiments is shown along with the highest confidence level 
that was significant.  Figure 46 shows the brightness of CD11c for these two experiments 
displayed in a histogram.  Mock infected is labeled in black, red is infectious virus, and 
blue is inactivated virus.  A clear increase in CD11c is seen in the DC with the virus 
versus the mock controls.  
Table 10: CD11c mean brightness of DC infection, 10 MOI infectious and heat 
inactivated virus corresponding to 10 MOI of infectious virus and mock infected controls.   
Sample Mean Confidence Level p value 
Optimized DC infection Donor C experiment 1 
Mock Infected 12,111 - - 
10 MOI Infectious 49,772 80% 0.2 
10 MOI Inactivated 32,135 70% 0.3 
Optimized DC infection Donor C experiment 2 
Mock Infected 8,183 - - 
10 MOI Infectious 51,935 95% 0.05 






In summary, the increase in brightness of CD11c indicates a difference in the 
expression of CD11c on DCs infected with H1N1 compared to cells that were loaded with 
the same quantity of inactivated virions.  
  
Figure 46: Brightness of CD11c for two experiments.  Graph on the left from 
experiment 1, graph on the right from experiment 2.  DC with 10 MOI 
infectious virus had the brightest CD11c (red) followed by the DC with 








 Influenza A virus infections continue to cause significant morbidity and mortality.   
Extensive vaccine production time, viral antigenic variability, and low vaccine efficacy   
contribute to the annual influenza pandemics and seasonal epidemics.  A better 
understanding of human immune responses to Influenza A strains could result in more 
effective next generation vaccines. 
The specific aim of this study was to determine the expression of activation 
markers in H1N1-infected DCs.  To this end, influenza virus was propagated to make a 
stock for future experiments.  This was done successfully in tissue culture using MDCK 
cells. MDCK-propagated virus was titrated by two different methods: hemagglutination 
and a Tissue Culture Infectious Dose 50% (TCID50) assays.  H3N2 could not be grown in 
MDCK cells as efficiently as H1N1.  Shown in Table 3 the stock H3N2 from the IRR had 
almost four times more total viral particles then the stock H1N1, as determined by a HAU 
titer of 128 in H3N2 compared to 32 in H1N1.  However, H3N2 had less of infectious 
particles with a titer of 3.9x104 PFU/ml versus H1N1 titer of 3.9x10
5 PFU/ml.  These 
results show that the virus stocks of H3N2 had more noninfectious particles than H1N1.  
MDCK cells were used to propagate this stock virus.  Infectious particles are required for 
a productive infection and propagation.  A competition between non-infectious and 
infectious virions could result in interference as seen in the lack of development of CPE 
with H3N2 in MDCK cells.  Consequently, we used H1N1 in the experiments involving 
the viral infection of dendritic cells. 
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A method was optimized to separate monocytes from mononuclear cells with high 
yield and purity (up to 95%).  These monocytes were then placed into tissue culture with 
optimized concentration of cytokines GM-CSF and IL-4 to produce monocyte derived 
dendritic cells (DCs).  These DCs were infected with A/California/07/2009 (H1N1pdm), 
and checked for the expression of activation markers.   
We hypothesized that the immune response against infectious virus induces a 
different pathway than inactivated virus.  This will have an impact on the antibody 
response against virus presented in two different ways by DCs.  Therefore, a difference in 
marker expression was expected to be observed when comparing the DCs that were 
infected with 10 MOI of infectious virus and a quantity corresponding to 10 MOI of 
inactivated virus.  
Results in Table 10 demonstrate a four to six fold increase in mean brightness of 
the CD11c marker for the actively infected dendritic cells compared to mock-infected 
controls. However, DCs which were treated with a quantity corresponding to 10 MOI of 
inactivated virus showed approximately a 3 fold increase in mean brightness for the 
CD11c marker compared to mock infected controls. 
CD11c, a marker for DCs, binds CD54, or Intracellular Adhesion Marker 1.  
These are both involved in cellular activation, particularly in activation of T cells, and 
enhancement of the immune response. When a DC is infected with infectious virus, the 
virus will use the cellular machinery to replicate itself. By increasing the expression of 
CD11c, the DC initiates a cascade of events that includes activation of T cells.  We have 
demonstrated that this increase in expression of CD11c is occurring in DC infected with 
virus, but it is also occurring at a lower amount in DCs loaded with inactivated H1N1 
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virus.  The inactivated virus will not replicate to produce infectious particles inside a 
target cell, and thus is generating a response similar to inactivated flu vaccines.  Our 
observations positively correlates with the lower immune response induced by the 
inactivated vaccines. 
We would expect to see an increase in activation markers such as CD40 and 
HLA-DR (MHC Class II) in infected DCs, but in these experiments enhanced expression 
was not observed.  MHC Class II on antigen-presenting cells like DC, presents 
extracellular antigens to T helper cells, which is required for adaptive humoral immunity 
to H1N1.  The experiment conducted to determine activation marker expression was 
designed to study these markers 4 hours post infection.  It is conceivable that expression 
of other activation markers may require additional time post infection. Future studies may 
involve longer infection time to study this. MHC II and CD40 molecules are involved in 
the specific and second signal for activation of T cells respectively. Whereas CD11c is 
involved in the recruitment of T cells. Therefore, expression of adhesion molecule CD11c 
early (4 hours after infection) seems like the first step of a logical sequence of events in 
the overall mechanism of activation of T cells. The higher expression of CD11c in 
infected cells compared to dendritic cells loaded with inactivated virus is in agreement 
with a stronger response against viral infection compared to inactivated vaccines. 
The future goal of this research is to understand the interaction between different 
populations of human B cells in DCs loaded with inactivated virus as well as infected 
DCs in the antibody response to Influenza A infection in vitro.  For this purpose, a 
method was optimized to separate B cells from mononuclear cells. Minority B cell 
populations were also identified and analyzed successfully, providing for future study of 
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MZBCs, a B cell population of interest involved in the early immune response.  Sensitive 
H1 and H3 specific ELISA assays were developed which enabled detection of IgM, and 
subclasses IgG1, IgG2, IgG3, and IgG4.  Detection of these Influenza A-specific 
subclasses will be useful when studying formation of these antibodies in the co-culture of 
influenza infected DCs and different B cell populations.  This in vitro model will provide 
a better understanding of the early innate immune responses to Influenza A including the 
cellular interactions required for successful resolution of H1N1 infection.  Ultimately 
information derived from these studies may help in the development of more effective 






















Consent form for healthy volunteers  
 
TITLE:  
Marginal Zone B Cells in the early antibody response to influenza infection in humans 
 
AGREEMENT TO PARTICIPATE:  
This signed consent is to certify my willingness to participate in this investigational (research) study. 
 
PURPOSE OF STUDY:  
The purpose of this research is to study the induction of antibodies upon infection with influenza in vitro. I am being 
asked to donate blood because I do not have an active influenza infection at this time. 
 
TREATMENT(S)/PROCEDURE(S):  
I will be asked to donate approximately 30 milliliters of blood (~2 tablespoons) on three different occasions (at least one 
month apart) over period of a year. This blood will be collected by venipuncture (using a needle to obtain blood from my 
arm). Blood will be collected by a trained professional at Wright State University. 
 
BENEFITS AND RISKS: 
The potential risks associated with venipuncture are excessive bleeding, fainting, feeling light-headed, development of a 
hematoma (bruising caused by blood accumulating under the skin), and infection (a slight risk any time the skin is 
broken). There may be a need for multiple punctures to locate a vein. I understand that there is no direct benefit to me 
other than helping to increase understanding influenza infection.  
 
COSTS:  
There will be no costs to me for my participation in this study. 
 
REMUNERATION:  





The researchers will be collecting demographic information about me (name, age, sex). All this information will be kept 
locked to maintain confidentiality. My identity will not be disclosed in any publication, or directly on the samples. 
 
WHOM TO CONTACT:  
If I have questions about this research study, or have a research-related injury to report, I can contact the researcher 
Cheryl Conley at 937-775-2306.  If I have general questions about giving consent or my rights as a research participant 
in this research study, I can call the Wright State University Institutional Review Board at 937-775-4462. 
 
VOLUNTARY CONSENT:  
I understand that I am free to refuse to participate in this study or to withdraw at any time.  My decision to participate or 
to not participate will not adversely affect relationship to this institution or cause a loss of benefits to which I might 
otherwise be entitled. 
 
My signature below means that I have freely agreed to participate in this 
investigational study. 
 
SIGNATURE/DATE LINES:          
 (Typed Name/Signature of Participant)   (Date) 
  
          









Appendix B: Reagent List 
Bicarbonate buffer: 
 1.59 g Na2CO3, 2.93 g NaHCO3 
 Fill up to 1 L volume distilled water, pH to 8.6, store at room temperature. 
10x PBS Buffer: 
2.28 g NaH2PO4, 11.5 g Na2HPO4, 43.84 g NaCl, 400 ml of dH2O, pH to 7.0. Fill 
up to 500 ml final volume with distilled water, store at room temperature. 
1x PBS Buffer: 
 12.5 ml of 10x PBS and 112.5 ml of distilled water, store at room temperature. 
1x PBS- 0.1% Tween wash buffer (sterile):  
 1125 µl of 1x PBS- 10% Tween, Fill up to 125 ml with 1x PBS, store at room 
 temperature. 
Blocking Buffer: 
 5% non-fat dry milk in 1x PBS-0.1% Tween.  2.25 g of Kroger or Meijer non-fat 
 dried milk, 1125 µl of 1x PBS- 10% Tween.  Fill up to 45 ml with 1X PBS buffer.  
 Store on ice or frozen overnight (wrap cap in parafilm if freezing). 
Cell Buffer: 
 1% BSA 1mM EDTA 1xPBS 
Flow Fixing Solution: 
 1% PFA 1mM EDTA 1xPBS 
1x Homemade Red Blood Cell Lysis Buffer: 
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 150mM NH4Cl 
 10mM KHCO3 
 1mM EDTA 
Separation and Labeling Buffer: 
 0.5% Biotin free BSA 2mMEDTA 1xPBS 
20x DC Production Media: 
1.25 µl of BD Pharmigen Recombinant Human IL-4 (CAT#554605, 100 µg/ml, 
0.4-5x108 units/mg) 
0.4 µl of BD Pharmigen Recombinant Human GM-CSF (CAT# 550068, 200 
µg/ml, 0.1-1x109 units/mg) 
1% Penicillin-Streptomycin (100 units/ml Pen and 100 µg/ml Strep) (Pen-Strep) 
10% Heat-inactivated fetal calf serum (FCS) 
 Up to a final volume of 5 mls of 1xDMEM 
Dynabead Buffer: 
 0.1% Biotin free BSA 
 2mM EDTA 
 1xPBS 
DMEM-5: 
 1% Pen-Strep (stock 1,000 U/ml Pen 1mg/ml Strep) 
 5% FCS 
 1x Dulbecco’s Modified Eagle Medium (DMEM) 
DMEM-10: 
1% Pen-Strep (stock 1,000 U/ml Pen 1mg/ml Strep) 
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 10% Heat-inactivated fetal calf serum 
 1x FCS 
Wash Medium: 
 1% Pen-Strep (stock 1,000 U/ml Pen 1mg/ml Strep) 
 1xDMEM 
TPCK-Treated Trypsin Working Stock: 
 2 mg/ml TPCK-Treated Trypsin 
 1xDMEM 
Influenza Virus Growth Media 
 2 µg/ml TPCK-Treated Trypsin 
 1% Pen-Strep 
 1xDMEM 
TCID50% Viral Dilution Media 
 1 µg/ml TPCK-Treated Trypsin 














Name CAT# Lot# Dilution 
Method #1 Pierce Goat 
Anti-Human 
IgG Lambda 
31131 ME1418821 1:40 
Method #1 Pierce Goat 
Anti-Human 
IgG Kappa 



































555882 02539 1:1000 
Method #1 Pierce Goat 
Anti-Human 
IgG Peroxidase 
31413 ML1490538 1:5000 




555784 10689 1:50 




555868 19501 1:100 




555873 04895 1:100 
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555790 05989 1:1000 





555794 00529 1:1000 







FR-1184 1314H1AG 1:50 






FR-43 58685890 1:50 




555781 E03419-1634 1:500 








FR-54 61807464 1:50 







A H1 pdm091 
FR-572 61807466 1:50 
Method #3 Influenza 
Reagent 


















32430 OE185747 1:500 
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